Living with myasthenia gravis – or supporting someone who is – can be challenging and overwhelming. If you’re looking for understanding, practical support, and guidance beyond medical care, you’re in the right place.
Myasthenia gravis (MG) is a chronic neuromuscular disorder that causes muscle weakness and fatigue. It affects voluntary muscles – the ones we use for everyday activities like speaking, chewing, swallowing, moving, and breathing.
MG is caused by an autoimmune response that disrupts communication between nerves and muscles. While there is no cure, many people with MG are able to manage symptoms effectively with treatment and support.
MG affects each person differently. Symptoms may change from day to day and often worsen with activity or at the end of the day.
People with MG experience:
Living with MG often means adjusting routines, managing energy, and navigating physical and emotional changes.
A diagnosis of myasthenia gravis can raise many questions, not just medical ones. Many people tell us they feel isolated, misunderstood, or unsure where to turn once appointments end.
That’s where we come in.
Muscular Dystrophy Canada provides non-medical support for people across Canada living with most types of neuromuscular disorders, including myasthenia gravis. We help by providing:
We meet people where they are — whether newly diagnosed, adjusting to changes, or supporting a loved one. Our support is confidential, free, and tailored to your needs.
Understanding what comes before and after a diagnosis is a big part of feeling informed and supported. You may have questions about what living with myasthenia gravis can be like at different stages, or about current research and emerging treatments.
We offer resources to help.
Hear about common experiences and support needs at different stages of living with MG.
Hear from neuromuscular experts about today’s treatment options and what’s ahead in MG research and clinical trials.
Our research hotline will provide you with reliable information about MG research and emerging treatments.